Addressing MRSA infection and antibacterial resistance with peptoid polymers

Jiayang Xie, Min Zhou, Yuxin Qian, Zihao Cong, Sheng Chen, Wenjing Zhang, Weinan Jiang, Chengzhi Dai, Ning Shao, Zhemin Ji, Jingcheng Zou, Ximian Xiao, Longqiang Liu, Minzhang Chen, Jin Li & Runhui Liu

Methicillin-Resistant Staphylococcus aureus (MRSA) induced infection calls for antibacterial agents that are not prone to antimicrobial resistance. We prepare protease-resistant peptoid polymers with variable C-terminal functional groups using a ring-opening polymerization of N-substituted N-carboxyanhydrides (NNCA), which can provide peptoid polymers easily from the one-pot synthesis. We study the optimal polymer that displays effective activity against MRSA planktonic and persister cells, effective eradication of highly antibiotic-resistant MRSA biofilms, and potent anti-infectious performance in vivo using the wound infection model, the mouse keratitis model, and the mouse peritonitis model. Peptoid polymers show insusceptibility to antimicrobial resistance, which is a prominent merit of these antimicrobial agents. The low cost, convenient synthesis and structure diversity of peptoid polymers, the superior antimicrobial performance and therapeutic potential in treating MRSA infection altogether imply great potential of peptoid polymers as promising antibacterial agents in treating MRSA infection and alleviating antibiotic resistance.
Methicillin-resistant *Staphylococcus aureus* (MRSA) is frequently encountered in hospitals and communities worldwide, with high morbidity and mortality, and is a formidable threat to human health. The sustained emergence and rapid spread of MRSA as well as the lack of new antibiotics imply the post-antibiotic era and an urgent call for novel antimicrobial agents. Host-defense peptides (HDPs) have been studied as promising potential therapeutic alternatives because of their broad-spectrum antimicrobial activity and low susceptibility to antimicrobial resistance. However, HDPs’ application is limited due to their innate shortcomings, including their low stability in the presence of protease, high cost, and time-consuming step-by-step synthesis. Therefore, peptide mimetics, as well as polymeric mimetics, have been studied to retain the favorable antimicrobial functions of HDPs and, in the meantime, to address HDPs’ shortcomings.

Peptoids have been studied as a class of peptide mimetics, with their structure differing from peptides only in that peptoids’ side chains are attached to the backbone amide nitrogen rather than to the α-carbon, which enables peptoids’ excellent stability in the presence of protease. Peptoids have been explored as antibacterial mimics of HDPs in precedent literatures, but with a very little report for in vivo demonstration. Moreover, these HDP mimicking peptides were mostly prepared from time-consuming step-by-step solid-phase synthesis.

In this study, we design and synthesize a series of peptoid polymers, poly-N-aminoethylglycine (poly-Naeg), via the convenient one-pot ring-opening polymerization (ROP) of α-amino acid N-substituted N-carboxyanhydrides (α-NNCAs) (Fig. 1a). The optimal peptoid polymer displays superior antibacterial properties: with effective activities against MRSA, persister cell killing, effective eradication of MRSA biofilms, and in vivo anti-infectious effectiveness in a mouse wound model, a mouse keratitis model, and a mouse peritonitis model induced by MRSA (Fig. 1b). It is noteworthy that bacteria are unable to acquire resistance against the peptoid polymer owing to the antibacterial mechanism, including the generation of reactive oxygen species (ROS).

**Results**

**Synthesis of peptoid polymers and in vitro antibacterial study.** A previous study indicated that the biological function of antimicrobial polymers can be tuned by their terminal functional groups, which inspired us to explore peptoid polymers with hydrophilic group PEG or hydrophobic groups, variable aromatic groups and variable alkyl chains. The N-substituted α-NNCA monomer, Nβ-Cbz-aminoethyl-NNCA (Supplementary Figs. 1–7), was polymerized using primary amines as the initiators followed by an acidic deprotection step to give 20 mer peptoid polymers, poly-Naeg, with variable C-terminal functional groups (Poly1 to Poly7) and narrow dispersities (Fig. 1a and Supplementary Figs. 8–14). We examined the activity of these poly-Naeg against multiple Gram-positive bacteria, including five strains of MRSA (*S. aureus* Mu50, *S. aureus* Newman, *S. aureus* USA400, *S. aureus* USA300 LAC, and *S. aureus* USA300) and three drug-sensitive species (*S. aureus* ATCC6538, *S. epidermidis* 49134, and *B. subtilis* BR-151). All poly-Naeg showed effective activity against these bacteria within our test, with thiol terminated Poly1 performing slightly better and having MIC (the minimum inhibitory concentration) values and MBC (the minimum bactericidal concentration) values in the range of 3.13–12.5 μg/mL and 3.13–25 μg/mL, respectively (Fig. 2a). We then took the thiol terminated Poly1 as the selected compound for more detailed studies.

We prepared thiol terminated poly-Naeg at variable chain lengths by controlling the ratio of initial monomer/initiator (DP = 5, 10, 20, 40; Fig. 2b and Supplementary Figs. 15–18, 26–29) and evaluated their activities against *S. aureus* ATCC6538. These poly-Naeg (HS(Naeg)$_n$) showed chain length-dependent antibacterial activity, the longer polymers at 20 and 40 mer showing a better activity with MIC of 12.5 μg/mL (Fig. 2c). Although both HS(Naeg)$_{20}$ and HS(Naeg)$_{40}$ showed low hemolysis and cytotoxicity, HS(Naeg)$_{20}$ was superior to HS(Naeg)$_{40}$ in having HC$_{50}$ (the minimum concentration to cause 50% hemolysis) value over 10000 μg/mL, IC$_{50}$ (the minimum concentration to cause 50% reduction in cell viability) value of 400 μg/mL, and high antibacterial selectivity index (HC$_{50}$/MIC > 800 and IC$_{50}$/MIC = 32) (Fig. 2d–g). The optimal peptoid polymer HS(Naeg)$_{20}$ was further tested on other different clinically isolated Gram-positive strains. The polymer is active against these Gram-positive bacteria with MIC values in the range of 1.56–25 μg/mL. In sharp contrast, most of the clinically isolated strains we tested were drug-resistant or even multiple drug-resistant (Table 1). It’s noteworthy that the MIC and MBC values of the peptoid polymer keep almost constant when tested in the presence of serum or other biological mediums.
 salts used to simulate the physiological environment (Supplementary Fig. 34 and Supplementary Table 1).

**Antibacterial mechanism.** To figure out the antibacterial mechanism of poly-Nae, we did cytoplasmic membrane depolarization test using DiSC3(5) dye as the indicator and found that HS(Nae)_{20} only displayed a moderate membrane depolarization effect on S. aureus (Fig. 3a). To get more detailed mechanistic information using time-lapse fluorescent confocal imaging, we prepared a morpholino-naphthalimide dye functionalized poly-Nae, dye–(Naeg)_{20}, via N-(3-aminopropyl)-4-morpholin-1,8-naphthalimide initiated NNCA polymerization followed by deprotection under acidic conditions (Supplementary Figs. 30–33). Incubating S. aureus with dye–(Naeg)_{20} (green fluorescence) at 1 × MBC concentration and propidium iodide (PI, red fluorescence), we observed that the polymer entered into cytoplasm directly from ~400 s without strong enrichment on the cell membrane and without PI signal (Fig. 3b, c), which echoed the weak membrane depolarization conclusion above and implied an antimicrobial mechanism without strong direct interactions between the polymer and bacteria membrane. We hypothesize that peptoid polymer penetrates membrane possibly through direct translocation like some cationic antimicrobial peptides reported in precedent literature: the interaction of the positively charged polymer with negatively charged components of bacteria membrane destabilizes the membrane bilayer, creating a transmembrane channel, thereby allowing the peptoid polymer to enter the bacterial cells without the membrane lysis\(^{55}\). About 300 s after the peptide polymer enriched in the cytoplasm, PI got into the cytoplasm and indicated the damage of bacteria membrane (Fig. 3b, c), which was supported by the front view of the Z-stacked image confirming colocalization of polymer with PI within bacteria (Fig. 3d).
We also found that the peptoid polymer HS(Naeg)$_{20}$ bound to DNA strongly even at a low N:P ratio of 1:1 (Fig. 3e), which may inhibit cellular functions and cause bacterial death. DNA binding may also lead to the production of ROS and kill bacteria by damaging bacterial membrane as reported in literatures$^{38,39}$. Using 2′,7′-dichlorofluorescin diacetate as the ROS indicator, we found the ROS level within S. aureus increased around 5.5-fold after the bacteria were incubated with HS(Naeg)$_{20}$ for 30 min. The addition of 10 mM ROS inhibitor N-acetyl-L-cysteine (NAC) suppressed intracellular ROS to normal cell level (Fig. 3f), which was accompanied by the loss of activity against S. aureus (MBC $>1000 \mu$g/mL) for HS(Naeg)$_{20}$ (Fig. 3g). The fact that the antioxidant reagent NAC blocks bacterial killing and that peptoid polymer kills bacteria much faster than do DNA-targeting antibacterial agents$^{58-60}$ suggests that bacterial killing of peptoid is associated with the generation of the high level of ROS, rather than just interaction or damage on DNA (Fig. 3g and Supplementary Fig. 40). These studies suggested the probable complex antibacterial mechanism of poly-Naeg including the generation of the high level of ROS and DNA binding$^{7,61,62}$. The generation of the high levels of ROS could kill bacteria by damaging bacterial membrane which was supported by the analysis using a scanning electron microscope (SEM) and transmission electron microscopy (TEM). SEM characterization on HS(Naeg)$_{20}$ (1 × MBC)-treated S. aureus showed obviously damaged bacterial membrane (Fig. 3h). TEM characterization on HS(Naeg)$_{20}$-treated S. aureus showed cytoplasm membrane damage and loss of cytoplasmic content (Fig. 3h).

**Table 1** Antibacterial activities against clinically isolated Gram-positive strains.

| Strains            | MIC (µg/mL) |
|--------------------|-------------|
|                    | HS(Naeg)$_{20}$ | Vancomycin | Methicillin | Norfl oxacin | Ampicillin |
| S. aureus 2904     | 6.25         | 0.39       | 6.25        | 200          | 25         |
| S. aureus 2802     | 6.25         | 0.39       | 6.25        | 200          | 25         |
| S. aureus 2902     | 6.25         | 0.39       | 12.5        | 25           | 25         |
| S. aureus 2202     | 6.25         | 0.78       | 3.13        | 50           | 1.56       |
| S. haemolyticus 1203 | 1.56     | 0.78       | $>200$      | 25           | 200        |
| S. haemolyticus 1107 | 25         | 0.78       | $>200$      | 100          | $>200$     |
| S. haemolyticus 0202 | 3.13      | 1.56       | 200         | 0.2          | 0.39       |
| S. epidermidis 9397 | 3.13        | 0.78       | 1.56        | 25           | 6.25       |
| S. epidermidis 0501 | 3.13        | 0.78       | 12.5        | 0.2          | 6.25       |
| E. faecium 2504    | 6.25         | 0.78       | $>200$      | 200          | 100        |
| E. faecium 0610    | 25           | 0.78       | $>200$      | 200          | $>200$     |
| E. faecium 1205    | 25           | 0.39       | $>200$      | 100          | $>200$     |
| E. faecium 0502    | 12.5         | $>200$     | $>200$      | 100          | $>200$     |
| E. faecium 0609    | 25           | 50         | $>200$      | $>200$       | $>200$     |
| E. faecalis 2305   | 25           | 0.78       | $>200$      | 25           | 12.5       |
| E. faecalis 0609   | 25           | 0.39       | 50          | 1.56         | 3.13       |
| S. agalactiae 0613 | 25           | 0.78       | 1.56        | 25           | 0.39       |
| L. monocytogenes 1001 | 12.5     | 0.39       | 25          | 1.56         | 1.56       |

Insusceptibility to antibacterial resistance and fast bacterial killing. Antibacterial resistance test on HS(Naeg)$_{20}$, the best antibacterial peptoid polymer with this study, showed that S. aureus did not acquire resistance upon exposure even after the bacteria was treated continuously with HS(Naeg)$_{20}$ at a sublethal dose for 834 passages; in sharp contrast, the MBC of norfloxacin increased by 1024 times after S. aureus was treated with norfloxacin for 375 passages (Fig. 4a). The time-kill kinetic study showed that HS(Naeg)$_{20}$ achieved about 2.7-log reduction of S. aureus within 60 min at a concentration of 1 × MBC. In sharp contrast, vancomycin caused only about 0.3-log reduction of the bacteria even after 4 h of treatment (Fig. 4b). Compared with conventional antibiotics, the fast bacterial killing is one of the advantages of our peptoid polymers, which is very important in the treatment of sepsis and other situations where there is an urgent need to kill bacteria.

Eradication of persister bacteria and biofilm. The ability of HS(Naeg)$_{20}$ to kill persister cells was evaluated, and the result showed that the peptoid polymer can effectively kill persister cells that is known to be a key reason for the high antimicrobial resistance associated with mature biofilms (Fig. 4c). The ability of HS(Naeg)$_{20}$ to kill persister cells encouraged us to explore this peptoid polymer for its activity against S. aureus biofilms, a formidable threat to human health due to the frequently encountered strong drug resistance$^{63,64}$. HS(Naeg)$_{20}$ efficiently inhibited the formation of S. aureus biofilms at a concentration as low as 1 × MIC; for two antibiotic controls, vancomycin and norfloxacin, required a concentration of 2 × MIC and 64 × MIC respectively to inhibit the formation of S. aureus biofilm (Fig. 4d). For the even more challenging mature biofilms of S. aureus, HS(Naeg)$_{20}$ eradicated the biofilms efficiently at a concentration of 8 × MIC; whereas, vancomycin and norfloxacin could not eradicate mature biofilms effectively even at a concentration up to 1024 × MIC and 2048 × MIC, respectively (Fig. 4e).

The in vivo anti-infectious efficacy of HS(Naeg)$_{20}$. Encouraged by the superior antibacterial performance of the peptoid polymers, we continued to evaluate the in vivo antibacterial efficacy of HS(Naeg)$_{20}$ in the mouse full-thickness wound model and the mouse keratitis model, including vancomycin and saline as the positive and negative control, respectively. In the wound infection model, MRSA suspension was applied to the wound and infected for 24 h followed by topical treatments with peptoid polymer. Compared with the saline group, HS(Naeg)$_{20}$ treatment led to a significant reduction in the bacterial burden on the wound (~2.0-log reduction), which is better than vancomycin treatment (~1.2-log reduction) (Fig. 5a). Besides, we also used the same model in immunosuppressed mice to explore the in vivo activity of HS(Naeg)$_{20}$ against other Gram-positive bacteria such as S. epidermidis and S. haemolyticus. It was found that the polymer performed the same as or even superior to did vancomycin for the infection caused by S. epidermidis and S. haemolyticus.
respectively (Fig. 5b, c). We also evaluated the in vivo antibacterial activity of HS(Naeg) 20 against biofilm in a MRSA keratitis model. In this model, the polymer reduced the bacterial load of each eye of the mouse by 2.5-log, while vancomycin was ineffective (Fig. 5d).

Furthermore, the mouse peritonitis model was employed to evaluate the therapeutic potential of HS(Naeg) 20 on systemic infection. Mice were infected by intraperitoneal injection of MRSA at a lethal dose (all untreated mice died within 12 h). Intraperitoneal injection of a single dose of polymer (20 mg/kg) can substantially increase the survival rate of infected mice (5/6 mice survived) and reduce the bacterial load in major organs, blood and peritoneal fluid, making it comparable to vancomycin in antibacterial efficacy (Fig. 6a, d). We also examined the typical pathological changes of the organs, and found that these changes were alleviated if with peptoid polymer treatment (Supplementary Fig. 38). Likewise, we examined the effectiveness of HS(Naeg) 20 to treat peritonitis infections induced by S. epidermidis and S. haemolyticus in immunosuppressed mice. In the peritonitis model of S. epidermidis (66.7% death in saline treatment),

**Fig. 3 Antibacterial mechanism study of poly-Naeg.**

a Cytoplasmic membrane depolarization by HS(Naeg) 20 at 1×MIC and 2×MIC concentrations.

b Time-lapse confocal fluorescence imaging on the interaction between S. aureus and dye-(Naeg) 20 at a concentration of 1×MBC, in the presence of PI.

c Fluorescence intensity versus time in green and red channels in ROI.

d Ortho view of Z-stack images in (b).

e The electrophoretic mobility shift assay of plasmid DNA and the mixture of plasmid DNA-complexes at different ratios of N:P (HS(Naeg) 20-DNA).

f Fluorescence intensity produced by S. aureus treated with PBS buffer, HS(Naeg) 20 (1 × MBC) and the combination of HS(Naeg) 20 (1 × MBC) and NAC (10 mM), in the presence of 2,7'-dichlorofluorescin diacetate (n = 3 per group). Data are presented as mean ± SD. ***P < 0.001 (Student’s t test).

g The MBC of HS(Naeg) 20 against S. aureus in the presence or absence of NAC (10 mM).

h SEM and TEM characterization respectively on S. aureus cells with and without HS(Naeg) 20 treatment at a concentration of 1 × MBC.
polymer treatment resulted in 100% survival of the mice (6/6 mice survived), which was better than vancomycin (4/6 mice survived) (Fig. 6b). When the infection was caused by S. haemolyticus (all untreated mice died within 60 h), both polymer and vancomycin treatment achieved 100% survival of the mice (Fig. 6c). In addition, the peptoid polymer was equally as effective as vancomycin in reducing the bacterial burden in organs, blood, and peritoneal fluid in both two models (Fig. 6d, e). Finally, in vivo toxicity studies showed that there were no obvious differences in clinically important biomarkers of liver and kidney and no apparent tissue damage at 2 and 7 days post treatment with HS(Naeg)20 compared with the blank control group (Fig. 6g and Supplementary Fig. 39). It is worth mentioning that numerous peptidomimetic polymers with antibacterial properties have been reported in precedent studies, but most of them were proof-of-concept demonstrations of in vitro antibacterial activity and simple in vivo studies. The low in vivo toxicity and high in vivo antibacterial efficacy in multiple animal models demonstrated that our optimal peptoid polymer is a promising candidate for therapeutic agents.

**Discussion**

Peptoids have been explored as promising antimicrobial mimics of host-defense peptides to address the formidable challenge of antibiotic-resistant bacterial infections. However, the popular step-by-step solid-phase synthesis of peptoids is high cost, time-consuming, and difficult for large-scale synthesis, which hindered the application of antimicrobial peptoids. Hereby, we report antibacterial peptoid polymers from the one-pot ring-opening polymerization of NNCA, with low cost, fast, and easy large-scale synthesis. These peptoid polymers displayed effective activities against the “super bugs” MRSA on both planktonic and persister cells and effectively inhibited MRSA biofilm formation. Even for the challenging mature MRSA biofilms that are highly resistant to antibiotics, such as vancomycin and norfloxacin, the selected peptoid polymer effectively eradicated the biofilms and killed MRSA inside. The peptoid polymer also displayed effectively in vivo anti-infectious function in three MRSA-infected animal models. Moreover, after repeated use of the antibacterial peptoid polymer at a sublethal dose for 834 passages, S. aureus did not
acquire resistance. These observations were consistent with the bacterial killing mechanism of the peptoid polymer. This highly favorable insusceptibility to antibacterial resistance, in addition to the structural versatility and aforementioned superior in vivo antibacterial performance of peptoid polymers, imply a great potential of peptoid polymers in developing antimicrobial agents and antimicrobial materials.

**Methods**

**Measurements.** Nuclear magnetic resonance (NMR) spectra were collected on an AVANCE III 400 spectrometer at 400 MHz or an Ascend 600 spectrometer at 600 MHz using CDCl3 or D2O as solvents. Chemical shifts were referenced to the resonance for residual protonated deuterated solvent. High-resolution electrospray ionization time-of-flight mass spectrometry (HREI-MS) was collected on a Waters XEVO G2 TOF mass spectrometer and high-resolution electron ionization time-of-flight mass spectrometry (HREI-MS) was collected on a Waters GCT Premier mass spectrometer. Gel permeation chromatography (GPC) was performed on a Waters GPC instrument equipped with an isotropic HPLC pump (Waters 1515), a Brokhaven BI-MwA multi-angle light scattering detector, and a refractive index detector (Waters 2414). N, N-dimethylformamide (DMF, supplemented with 10 μM LiBr) was used as the mobile phase at a flow rate of 1 mL/min at 50 °C. The GPC equipped by a Tosoh TSKgel Alpha-2500 column (particle size 7 μm) and a Tosoh TSKgel Alpha-3000 column (particle size 7 μm) linked in series. Relative number-average molecular weight, degree of polymerization (DP), and dispersity index (D) were calculated from a calibration curve using poly(methylmethacrylate) (PMMA) as standards. SEM images were characterized on a Hitachi S-4800 field emission SEM and TEM images were characterized on a FEI Tecnai Spirit TEM. Time-lapse fluorescent confocal imaging was performed using ZEISS LSM 880 with Airyscan system in ZEISS Microscopy Shanghai Customer Centers.

**Synthesis of N-[2-(benzyloxycarbonyl)amino]ethylglycine ethyl ester (compound 1)**

1-(Benzyloxycarbonyl)-2-aminoethane (3.9 g, 20.0 mmol) was dissolved in 150 mL dichromethane (CH2Cl2), followed by the addition of ethyl 2-bromooctadecanoate (3.3 g, 20.0 mmol) and triethylamine (2.2 g, 22.0 mmol) sequentially and the reaction was stirred at 55 °C for 12 h. After cooling to room temperature (rt), the reaction mixture was washed with deionization (DI) water three times (3 × 150 mL), and then the organic phase was dried over anhydrous MgSO4. After removing the solvent under the vacuum, the crude product was purified by silica gel column chromatography to obtain compound 1 as a yellow oil (3.0 g, 53.5% yield).1H NMR (400 MHz, CDCl3): δ 7.33–7.28 (m, 5H), 5.52 (br, 1H), 5.07 (s, 2H), 4.15 (q, J = 7.2 Hz, 2H), 3.35 (s, 2H), 2.01 (d, J = 5.6 Hz, 2H), 2.73 (t, J = 5.8 Hz, 2H), 1.87 (t, J = 7.2 Hz, 3H). HRESI-MS: m/z calculated for C14H20N2O4 [M]+: 280.1423; found: 280.1419.

**Synthesis of N-[2-(benzyloxycarbonyl)amino]ethyl-N-(di-t-butylcarbonyl)glycine (compound 2).** The synthesis of compound 2 was conducted by following a precedent procedure with modifications.66 Compound 1 (2.8 g, 10.0 mmol) was dissolved in 100 mL methanol (MeOH), followed by the addition of di-t-butyl dicarbonate (4.4 g, 20.0 mmol) to the reaction. The reaction mixture was heated to 60 °C and stirred overnight. After removing the solvent under the vacuum, an intermediate was obtained and used directly for the next reaction. The intermediate was dissolved in the mixed solvent of MeOH (60 mL) and tetrahydrofuran (THF; 20 mL), followed by the addition of 1.0 M NaOH solution to follow the mixture slowly. After stirring at rt for 5 h, the mixture was adjusted to pH 7 with 1.0 M HCl solution, and then the organic solvent was removed under vacuum. The residual aqueous phase was acidified by dropwise addition of 1.0 M HCl solution at 0 °C until pH 3–4. The mixture was extracted with ethyl acetate (EtOAc) (three times, each 20 mL), and then the combined organic phase was dried over anhydrous MgSO4 and concentrated under vacuum. The crude product was purified by silica gel column chromatography to obtain compound 2 as a white solid (3.9 g, 85.1% yield over two steps).1H NMR (400 MHz, CDCl3): δ 7.35–7.31 (m, 5H), 5.51 (br, 1H), 5.11 (s, 2H), 3.96 (s, 1H), 3.91 (s, 1H), 3.42–3.31 (m, 4H, 1.42 (d, J = 6.8 Hz, 9H). HREI-MS: m/z calculated for C14H24N2O6Na [M + Na]+: 273.1532; found: 273.1531.

**Synthesis of monomer N-[2-(benzyloxycarbonyl)amino]glycine-N-carboxyanhydride (N(Phe)-Cbz-aminoethyl-NNCA).** Compound 2 (2.0 g, 5.7 mmol) was dissolved in 100 mL anhydrous CH2Cl2 under a nitrogen atmosphere, followed by dropwise addition of phosphorus tribromide (1.5 g, 5.7 mmol) to the mixture at 0 °C. The reaction mixture was then warmed up to rt and stirred for 1 h. The reaction mixture was washed once with DI water (100 mL) quickly, and then the collected organic phase was dried over anhydrous MgSO4 and concentrated under vacuum. The crude product was recrystallized from a mixture of dichloromethane/hexane (v/v = 1:3) to obtain N-Phe-Cbz-aminoethyl-NNCA as a white needle-like crystal (0.8 g, 50.7% yield).1H NMR (600 MHz, CDCl3) δ 7.36–7.30 (m, 5H), 5.34 (br, 1H), 5.06 (s, 2H), 4.16 (s, 2H), 4.15 (q, J = 5.7 Hz, 2H), 3.38 (t, J = 6 Hz, 2H).13C NMR (150 MHz, CDCl3) δ 165.58, 157.09, 153.02, 136.26, 128.71, 128.42, 128.18, 67.19, 49.34, 43.82, 38.32. HREI-MS: m/z calculated for C15H24N2O4Na [M + Na]+: 301.0800; found: 301.0801.

**Synthesis of N-Cbz protected Poly(Naeg).** All polymerizations were carried out in a glove box under a nitrogen atmosphere. The C-terminal functional group of poly(Naeg)20 was introduced by using different amine initiators. The N-Cbz protected polymer was synthesized from a mixture of N-Cbz-aminoethyl-NNCA solution (0.18 mL) and 1-hexylamine solution (0.012 mL). The polymerization proceeded at rt until all monomers were completely consumed. Then the reaction mixture was diluted with 1 mL MeOH following by addition of cold petroleum ether (PE; 45 mL) to the mixture to precipitate out the polymer as white flocculent sediment. The polymer precipitate was collected by centrifugation and removal of the supernatant. After repeating three times of the above dissolution–precipitation process, the purified polymer was obtained. The N-Cbz protected polymers, with various C-terminal functional groups, were characterized by GPC using DMF as the mobile phase at a flow rate of 1 mL/min.

**Synthesis of N-Cbz protected HS(Naeg)20 at a variable chain length.** The N-Cbz protected HS(Naeg) at various chain length were prepared by controlling the ratio of monomer/initiator. The monomer N-Cbz-aminoethyl-NNCA and initiator 2-[(triphenylmethyl)thio]ethanamine were dissolved in anhydrous THF to a final concentration of 1 M and 0.5 M, respectively. The polymerization of hexylamine functionalized poly(Naeg)20 for example, the N-Cbz protected polymer was synthesized from a mixture of N-Cbz-aminoethyl-NNCA solution (0.18 mL) and 1-hexylamine solution (0.012 mL). The polymerization proceeded at rt until all monomers were completely consumed. Then the reaction mixture was diluted with 1 mL MeOH following by addition of cold petroleum ether (PE; 45 mL) to the mixture to precipitate out the polymer as white flocculent sediment. The polymer precipitate was collected by centrifugation and removal of the supernatant. After repeating three times of the above dissolution–precipitation process, the purified polymer was obtained. The N-Cbz protected polymers, with various C-terminal functional groups, were characterized by GPC using DMF as the mobile phase at a flow rate of 1 mL/min.
**Fig. 6** HS(Naeg)$_{20}$ displayed in vivo antibacterial efficacy without toxicity in the mouse peritonitis model. Bacteria suspension was i.p. injected and treatments were administered i.p. at 1 h post infection including, saline, HS(Naeg)$_{20}$ (20 mg/kg), and vancomycin (20 mg/kg). For infections caused by *S. epidermidis* and *S. haemolyticus*, immunosuppressed mice were used. **a–c** Survival rates (7 days) of mice in the peritonitis model induced by MRSA, *S. epidermidis*, and *S. haemolyticus*, respectively. $n = 6$ (six mice in each treatment group in three types of bacterial infection models). **d–f** CFU of bacteria in different organs, blood, and IP fluid in the peritonitis model induced by MRSA, *S. epidermidis*, and *S. haemolyticus*, respectively. $n = 6$ (six mice in each treatment group in three types of bacterial infection models). **g** Blood biochemical analysis at 2 and 7 days post treatment with HS(Naeg)$_{20}$. The untreated mice served as a blank control ($n = 5$ mice per group). Data are presented as mean ± SD. *$P < 0.05$, **$P < 0.01$, ***$P < 0.001$; n.s. (not significant) represents $P > 0.05$ (Student’s t test).
The poly(Naeg)20 was serially diluted by MH medium in a 96-well plate, and an 0.5 M, respectively, as the working solution. Dye-conjugated poly-Naeg was synthesized using the reported methods with modifications. B.4: Bromo-1,8-naphthalic anhydride (2.8 g, 10 mmol) and morpholine (1.3 g, 15 mmol) was dissolved in methoxylethanol (50 mL) and then the reaction mixture was stirred at 160 °C for 12 h under a nitrogen atmosphere. After cooling to rt, DI water was added to the reaction mixture to precipitate out the intermediate as a yellow solid. The intermediate was dried under vacuum for 12 h, and then mixed with trimethyloxysilane (7.4 g, 100 mmol) and 100 mL DI water followed by stirring at 110 °C for 16 h. After the removal of most of the solvent, the crude product was purified by silica gel column chromatography to obtain N-(3-aminopropyl)-1,8-naphthalimide as a yellow solid (0.95 g, 28.0% yield over two steps). 1H NMR (400 MHz, CDCl3): δ 8.58 (dd, J = 1.2, 7.2 Hz, 1H), 8.52 (d, J = 8.0 Hz, 1H), 8.42 (dd, J = 1.2, 8.4 Hz, 1H), 7.70 (t, J = 7.8 Hz, 1H), 7.23 (d, J = 6.8 Hz, 2H), 4.26 (t, J = 6.8 Hz, 2H), 4.02-4.00 (m, 4H), 3.37-3.25 (m, 4H), 2.75 (t, J = 6.6 Hz, 2H), 1.92-1.86 (m, 4H). HRESI-MS: m/z calculated for C36H32N4O6 [M + H]+: 534.2361; found: 534.1660.

Synthesis of dye-(Naeg)n. The monomer N6-Chz-aminoethyl-NNCA and the initiator dye–NH2 were dissolved in anhydrous THF at a concentration of 1 M and 0.5 M, respectively, as the working solution. Dye-conjugated poly-Naeg was synthesized by following the aforementioned protocol from a mixture of N6-Chz-aminoethyl-NNCA solution (0.18 mL) and dye–NH2 solution (0.012 mL). After the monomer has been consumed, the reaction mixture was directly characterized by reverse phase GPC using DMF as the mobile phase at a flow rate of 1 mL/min. The polymer was depurified and purified by following the aforementioned protocol to give the purified dye-(Naeg)n as a yellow solid that is characterized by 1H NMR.

Bacterial strains. MRSA (S. aureus Mu50), S. aureus Newman, S. aureus USA400, S. aureus USA300, LAC, S. aureus USA300 were obtained from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. All clinically isolated Gram-positive bacteria used in this study were isolated from patients with various infections, different ages and sexes in the Shanghai Ruijin Rehabilitation Hospital. All strains were cultured in Luria-Bertani (LB) medium at 37 °C before use.

MIC and MBC assay. Bacteria were cultured in LB medium at 37 °C for 10 h, and then the bacterial suspension was diluted in Mueller–Hinton (MH) medium to a cell density of 2 × 10^8 colony forming units (CFU)/mL as the working suspension. The poly(Naeg)20 was serially diluted by MH medium in a 96-well plate, and an equal volume of bacterial suspension was added into each well. The final concentration of the poly(Naeg)20 was ranging from 200 to 1.56 μM, respectively, as the working solution. Dye-conjugated poly-Naeg was synthesized using the reported methods with modifications. The hemolysis experiment was approved by the Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. Human blood donors were informed of the hemolysis study and consent was obtained. Human blood was diluted with Tris-buffered saline (TBS, pH = 7.2) and centrifuged at 1700 g for 3 min. The human red blood cells (hRBCs) were collected and washed with TBS three times and then diluted to a working concentration of 5% (v/v). The HS(Naeg)n was serially diluted by TBS in a 96-well plate, and then an equal volume of hRBCs suspension was added into each well. The final concentration of the HS(Naeg)n was ranging from 10,000 to 78 μg/mL, and the plates were incubated at 37 °C for 1 h. After centrifugation, 80 μL of the supernatant in each well was transferred to a new 96-well plate and the OD value was collected on a microplate reader. Wells containing the mixture of Triton X-100 (3.2 μg/mL in TBS) and hRBCs were used as the positive control; wells containing hRBCs only were used as the blank. The percentage of hemolysis was calculated from:

\[
\% \text{ hemolysis} = \frac{A_{\text{polymer/blank}}}{A_{\text{HS(Naeg)/blank}} \times 100}
\]

Cytoxicity assay. NIH 3T3 fibroblast cells (ATCC CRL-1658) were cultured in TCPS Petri dishes using Dulbecco’s modified eagle medium (DMEM) at 37 °C in the presence of 5% CO2. Subconfluent monolayer culture was trypsinized and then cells were suspended in a growth medium containing serum. After centrifuged at 200 g for 4 min, cells were collected and resuspended in DMEM and diluted in DMEM to a cell density of 1 × 10^5 cell/mL as the working suspension. An aliquot of 100 μL of the cell suspension was added into each well of a 96-well plate and the plate was incubated at 37 °C overnight in presence of 5% CO2. After removing the old medium, fresh DMEM containing HS(Naeg)n, at various concentrations was added to corresponding wells for another 24 h incubation. An aliquot of 10 μL of dimethyl sulfoxide (DMSO) was added to dissolve the purple solid. Wells containing cells and without polymer were used as the positive control; wells containing DMEM only were used as the blank. The OD values were collected at 570 nm on a microplate reader and the percentage of cell viability was calculated from:

\[
\% \text{ cell viability} = \frac{A_{\text{polymer/blank}}}{A_{\text{DMSO/blank}} \times 100}
\]

to evaluate the cytotoxicity of the HS(Naeg)n.

Antimicrobial-resistance test. The antimicrobial-resistance test was conducted according to the previously reported method with slight modification. S. aureus ATCC6538 was cultured in LB medium at 37 °C for 10 h and then the bacteria suspension was diluted 400-fold in LB medium containing HS(Naeg)n (0.5 × MBC or norfloxacin (0.5 × MBC), respectively, followed by incubation at 37 °C under shaking for 24 h. An aliquot of 2.5 μL of the mixture was sampled and diluted 400-fold in LB medium for a new cell-drug incubation cycle. The above cycle was repeated every 24 h. The MBC values of HS(Naeg)n and norfloxacin against S. aureus ATCC6538 were examined every 4 days. Based on the MBC value determined by the test, the concentration of polymer and norfloxacin throughout the antimicrobial-resistance study was adjusted to keep at 0.5 × MBC, respectively.

Generation of bacterial growth was calculated from incubating time and bacteria growth kinetics described below. An increase in MBC shows the development of drug resistance.

Bacteria growth Kinetics. S. aureus ATCC6538 was cultured in LB medium at 37 °C for 10 h, and then the bacterial suspension was diluted in MH medium to a cell density of 2 × 10^8 CFU/mL as the working suspension. The bacteria suspension was exposed to an equal volume of HS(Naeg)n and norfloxacin solution at a final concentration of 0.5 × MBC at 37 °C. At various time points of treatment, the bacteria samples were diluted for plating on LB agar plate. After incubation at 37 °C for 14 h, the number of colonies on the plate was counted to calculate the rate of bacterial growth.

Study on bacterial killing kinetics. S. aureus ATCC6538 was cultured in LB medium at 37 °C for 10 h, and then the bacterial suspension was diluted in MH medium to a cell density of 2 × 10^8 CFU/mL as the working suspension. The bacteria suspension was treated with an equal volume of HS(Naeg)n or vancomycin solution at final concentrations of 1× and 2× MBC at 37 °C. At various time points of treatment, the bacterial samples were diluted for plating on LB agar plates. Then the plates were incubated at 37 °C for 14 h for CFU counting and viability calculation. The test was independently repeated at least three times.

Kill kinetics on persistor cell. S. aureus USA300 was cultured in LB medium at 37 °C for 6 h, and then the bacterial suspension was diluted in MH medium to a cell density of 1 × 10^8 CFU/mL as the working suspension. 1 mL of bacterial suspension was treated with ciprofloxacin at a concentration of 10 μM at 37 °C for 18 h. Half of the bacterial suspension was washed to remove antibiotics and treated with HS(Naeg)n at 4 × MIC at MH medium. The rest bacterial suspension
continued to be treated with ciprofloxacin as the control. At various time points of treatment, the bacteria samples were washed to remove the antibacterial agents and then diluted for plating on LB agar plate. Then the plates were incubated at 37 °C for 14 h for CFU counting and viability calculation.

Inhibition study on biofilm formation. *S. aureus* USA300 was cultured in LB medium at 37 °C for 10 h, and then the bacterial suspension was diluted in MH medium (containing 1% glucose and 1% NaCl) to a cell density of 2 × 10^8 CFU/mL. The plate was incubated at 37 °C for 24 h, and then the culture medium was removed, washed with PBS once, followed by adding 100 μL MTT solution (0.5 mg/mL) into the corresponding well. After further incubation at 37 °C for 4 h in the dark, the MTT solution was removed. An aliquot of 100 μL DMSO was added to each well to solubilize the purple solid and then the OD value was collected at 622 nm on a microplate reader. Wells containing inoculum and without antibacterial agents were used as the positive control; wells containing only MH medium were used as the blank. The percentage of surviving cells within biofilm was calculated from the following equation:

$$\% \text{ cell viability} = \frac{A^{\text{control} - \text{blank}} - A^{\text{blank}} \times 100}{A^{\text{control} - \text{blank}}}$$

The test was independently repeated at least three times.

Activity against mature biofilm. *S. aureus* USA300 was cultured in LB medium at 37 °C for 10 h, and then the bacterial cells were inoculated in a tissue culture-treated 96-well plate at initial densities of 10^7 CFU/mL. The plate was incubated at 37 °C for 24 h to allow biofilm formation. After the old medium was removed, the fresh MH medium containing various concentrations of HS(Naeg)20 and antibiotics (norfloxacin and vancomycin) were serially diluted with MH medium (containing 1% glucose and 1% NaCl) in a tissue culture-treated 96-well plate, and then an equal volume of bacterial suspension was added into each well. The plate was incubated at 37 °C for 24 h, and then the medium culture was removed, washed with PBS once, followed by adding 100 μL MTT solution (0.5 mg/mL) into the corresponding well. After further incubation at 37 °C for 4 h in the dark, the MTT solution was removed. An aliquot of 100 μL DMSO was added to each well to solubilize the purple solid and then the OD value was collected at 570 nm on a microplate reader. Wells containing inoculum and without antibacterial agents were used as the positive control; wells containing only MH medium were used as the blank. The percentage of surviving cells within biofilm was calculated from the following equation:

$$\% \text{ cell viability} = \frac{A^{\text{control} - \text{blank}} - A^{\text{blank}} \times 100}{A^{\text{control} - \text{blank}}}$$

The test was independently repeated at least three times.

Cytoplasmic membrane depolarization assay. The cytoplasmic membrane depolarization assay was conducted according to the previously reported method with slight modification77. *S. aureus* ATCC6538 was cultured in LB medium at 37 °C for 6 h, and then the bacterial suspension was diluted in HEPES medium (15 mM HEPES, 20 mM glucose, pH = 7.4) to a cell density of 10^8 CFU/mL as the working suspension. The bacteria suspension was incubated with 0.8 μM DiSC3(5) for 1 h, followed by the addition of KCl to a final concentration of 0.1 M to balance the cytoplasmic and external K+ concentration. An aliquot of 90 μL of the suspension was placed in a 384-well plate and then changes in fluorescence intensity were recorded on a microplate reader (excitation λ = 460 nm, emission λ = 530 nm). When the fluorescence intensity remained stable, an aliquot of 10 μL of HS(Naeg)20 solution (2 × MBC) was added to a final concentration of 1 × MIC. The mixture was incubated at 37 °C for 30 min. An aliquot of 10 μL of the HS(Naeg)20 treated and untreated bacteria were collected by centrifugation at 1700 × g for 5 min. Then the OD673 nm was measured, then fixed with 4% glutaraldehyde in PB at 4 °C overnight. The bacteria were further washed with PBS and dehydrated with gradient ethanol (30%, 50%, 70%, 80%, 90%, and then 100% ethanol). The samples were dried in air and then used for FESEM characterization.

TEM characterization of bacteria morphology. *S. aureus* ATCC6538 was cultured in LB medium at 37 °C for 10 h, and then the bacterial suspension was diluted in MH medium to a cell density of 10^9 CFU/mL as the working suspension. An aliquot of 10 μL of the HS(Naeg)20 solution (4 × MBC) and an equal volume of the bacterial suspension were mixed in a sterile Eppendorf tube, and then the mixture was incubated at 37 °C for 30 min. An aliquot of 90 μL of the working suspension was added as the control. HS(Naeg)20 treated and untreated bacteria were collected by centrifugation at 1700 × g for 5 min. Then the OD673 nm was measured, then fixed with 4% glutaraldehyde in PB at 4 °C overnight. The bacteria were further washed with PBS and dehydrated with gradient ethanol solutions (30, 50, 70, 80, 90, 95, and then 100% ethanol) for 1 h. The cells were further washed with PB and dehydrated with gradient ethanol solutions (30, 50, 70, 80, 90, 95, and 100% ethanol). Subsequently, the samples were treated sequentially with acetone for 20 min, the mixture of embedding agent and acetone (v/v = 1/1) for 1 h, the mixture of embedding agent and acetone (v/v = 1/1) for 3 h, and then the embedding agent overnight. After embedding, the samples were dehydrated in a series of acetone (70%, 80%, 90%, and 100%) and then embedded in acrylic resin. The sections were sectioned in a LEICA EM UC7 ultrathin slicer to obtain 70–90 nm sections. After being stained with lead citrate solution and 50% uranium dioxide-acetate saturated solution for 5 min, the sections were observed under the transmission electron microscope.

Mouse wound infection model. All animal procedures were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of the Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine and experiments were approved by the Animal Ethics Committee of the Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. The laboratory animal usage license number is SYXK-2016-0016, certified by Science and Technology Commission of Shanghai Municipality. This infection model was conducted according to the previously reported method with slight modification78. Female balb/c mice (20–21 g) were used in the full-thickness wound model caused by MRSA. Prior to surgery, mice were anesthetized with an intraperitoneal injection of sodium pentobarbital at a dose of 75 mg/kg. The dorsal hair was shaved, and the skin was rinsed with 75% alcohol three times. The 6-mm-diameter full-thickness wounds were punctured on either side of the back using a biopsy punch. An aliquot of 10 μL S. aureus USA300 LAC suspension (1.25 × 10^8 CFU/mL) was added to wound site. The wound site was covered by Tegaderm dressing (3 M, St Paul, MN) to prevent contamination. At 24 h post-infection, mice were randomly divided into three groups (seven animals per group) and then 15 μL of different treatment solutions were administered to the wound site: 0.9% saline (the negative control), HS(Naeg)20 (1.56 mg/mL) and vancomycin (1.56 mg/mL, the positive control). The treatments were applied every 4 h for a total of three times. After the last treatment for 4 h, mice were euthanized with an overdose of sodium pentobarbital. The wound sites were excised, weighed, and homogenized in PBS containing 0.1% TX-100. The homogenates were serially diluted for plating on LB agar. After incubation at 37 °C for 14 h, the number of colonies on the plate was counted to calculate the bacteria burden of wounds.
 aliquot of 10 µL of \( S. epidermidis \) 9397 suspension (1.45 \( \times 10^8 \) CFU/mL) or \( S. haemolyticus \) 0202 suspension (5 \( \times 10^8 \) CFU/mL) was added to the wound site. At 24 h post infection, mice were analyzed. The untreated group served as a blank control. At 7 days post treatments, the mice were euthanized and liver and kidney were collected for histological analysis.

**Results**

**Statistical and reproducibility.** Significance between the two groups was determined by two-tailed Student’s t test. All results were expressed as mean ± standard error. All micrograph assays were carried out at least three independent times with similar results.

**Data availability.** Data supporting the findings of this study are available within the article and its supplementary materials. Any other data that support the findings of this study are available from the corresponding author, upon reasonable request. Source data are provided with this paper.

**References**

1. Chambers, H. F. & Deleo, F. R. Waves of resistance: \( Staphylococcus aureus \) in the antibiotic era. *Nat. Rev. Microbiol.* 7, 629–641 (2009).
2. DeLeo, F. R., Otto, M., Kreiswirth, B. N. & Chambers, H. F. Community-associated meticillin-resistant \( Staphylococcus aureus \). *Lancet* 375, 1557–1568 (2010).
3. Nelson, R. Antibiotic development pipeline runs dry. New drugs to fight resistant organisms are not being developed, experts say. *Lancet* 362, 1726–1727 (2003).
4. Laxminarayan, R. et al. Antibiotic resistance—the need for global solutions. *Lancet Infect. Dis.* 13, 1057–1098 (2013).
5. Boman, H. G. Antibacterial peptides: key components needed in immunity. *Cell* 65, 205–207 (1991).
6. Zaslav, M. Antimicrobial peptides of multicellular organisms. *Nature* 415, 389–395 (2002).
7. Hancock, R. E. & Sahl, H. G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat. Biotechnol.* 24, 1551–1557 (2006).
8. Mishra, B., Reiling, S., Zarena, D. & Wang, G. Host defense antimicrobial peptides as antibiotics and design and application strategies. *Curr. Opin. Chem. Biol.* 38, 87–96 (2017).
9. Lee, E. Y. et al. Helical antimicrobial peptides assemble into protifibril scaffolds that present ordered diDNA to TLR9. *Nat. Commun.* 10, 1012 (2019).
10. Bray, B. L. Large-scale manufacture of peptide therapeutics by chemical synthesis. *Nat. Rev. Drug Discov.* 2, 587–593 (2003).
11. Sieprowska-Lupa, M. et al. Degradation of human antimicrobial peptide LL-37 by \( Staphylococcus aureus \)-derived proteins. *Antimicrob. Agents Chemother.* 48, 4673–4679 (2004).
12. Porter, E. A., Wang, X., Lee, H. S., Weisblum, B. & Gellman, S. H. Non-haemolytic beta-amino-acid oligomers. *Nature* 404, 565 (2000).
13. Liu, D. & DeGrado, W. F. De novo design, synthesis, and characterization of antimicrobial beta-peptides. *J. Am. Chem. Soc.* 123, 7553–7559 (2001).
14. Choi, S. et al. De novo design and in vivo activity of conformationally restrained antimicrobial arylamide foldamers. *Proc. Natl Acad. Sci. USA* 106, 9698–9703 (2009).
15. Verma, M. et al. Helical antimicrobial polypeptides with radially amphiphilic. *Proc. Natl Acad. Sci. USA* 112, 13155–13160 (2015).
16. Shi, Y. et al. gamma-AAAPeptides: design, structure, and applications. *Acc. Chem. Res.* 49, 428–441 (2016).
17. Ghosh, C., Sarkar, P., Samaddar, S., Uppu, D. & Haldar, J. L-lysine based lipidated biphenyls as agents with antibiofilm and anti-inflammatory properties that also inhibit intracellular bacteria. *Chem. Commun.* 53, 8427–8430 (2017).
18. Liu, Y., Ding, S., Dietrich, R., Marltbauer, E. & Zhu, K. A Biosurfactant-Inspired Heptapeptide with Improved Specificity to Kill MRSA. *Angew. Chem. Int. Ed.* 56, 1486–1490 (2017).
19. Niu, Y. et al. Rational design of dimeric lysine N-alkylamides as potent and broad-spectrum antibacterial agents. *J. Med. Chem.* 61, 2865–2874 (2018).
20. Ilker, M. F., Nusslein, K., Tew, G. N. & Coughlin, E. B. Tuning the hemolytic and antibacterial activities of amphiphilic polynorbornene derivatives. *J. Am. Chem. Soc.* 126, 15870–15875 (2004).
Author contributions
J.X., M.Z., and R.L. designed the experiments, evaluated the data, and wrote the manuscript together; Y.Q., W.J., Z.C., C.D., M.C., Z.J., and J.L. participated in the animal study; W.Z. conducted the time-lapse fluorescent confocal imaging; X.X. and L.L. participated in the antimicrobial assays; S.C. conducted the hemolysis assays; N.S. conducted the cytotoxicity assays; J.Z. performed DNA-binding assay; R.L. directed the project.

Competing interests
R.L. and M.Z. are co-inventors on a patent application covering the reported synthesis of polypeptoids and their antibacterial application. The remaining authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-26221-y.

Correspondence and requests for materials should be addressed to Runhui Liu.

Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021